Clearside Biomedical appoints Benjamin Yerxa, Ph.D. to Board of Directors

Clearside Biomedical, Inc.

Dr. Yerxa, CEO of Foundation Fighting Blindness and Clearside co-founder, appointed effective March 2, 2022.
Received option to purchase 30,000 shares at $1.49/share, vesting in 36 monthly installments.
Entitled to $40,000 annual retainer plus annual option grants for service as director.
His expertise expected to advance CLS-AX (axitinib) for wet AMD and SCS platform.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Benjamin Yerxa

director

CLSDQ · Clearside Biomedical, Inc.

Effective: 2022-03-03
Filed: March 3, 2022, 6:59 PM ET

the board of directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Benjamin Yerxa to serve as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Benjamin Yerxa was appointed as director at Clearside Biomedical, Inc..

Action: appointed
Role: director

Exact text from the filing

the board of directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Benjamin Yerxa to serve as a director of the Company, effective immediately.

View on SEC.gov

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-002728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.